> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Panel to Review Expanded Use for Pfizer’s Xeljanz
- URL: https://www.fdaweb.com/panel-to-review-expanded-use-for-pfizers-xeljanz/
- Published: 2017-07-10T12:00:00.000Z
- Updated: 2026-09-14T22:33:05.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139081

*Federal Register* notice: FDA has announced an 8/3 Arthritis Advisory Committee meeting that will review a Pfizer supplemental NDA for Xeljanz (tofacitinib) for treating adult patients with active psoriatic arthritis. The committee intends to discuss the efficacy and safety data and benefit-risk considerations. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-07-10/pdf/2017-14364.pdf?ref=fdaweb.com).